XML Template (2009) [5.9.2009–3:06pm] [1–12]
{TANDF_FPP}CMO/CMO_A_370883(NEW).3d (CMO) [First Proof]
Current Medical Research and Opinion
C213
Volume 25, Number 3 2008
3/4
(%)
Grade
4)
leucopenia)
(Grade
3/4 (Grade
Toxicity:
neutropenia
16.6 22 — 2.7
Survival
(months) — — 19 —
(%)
Stable
disease 27.8 — — 46
(%)
(
partial
RR response)
22.2 — 47 —
(
n
)
Patients 18 29 69 37
15;
and
and
and
1
2
;
and
q21d
mg;
8
mg/
8,
1–5,
added
tolerated
qd 200
1,
days
1,
2
days mg/m
po
1–5,
as
of
days
28
Dose days
i.v. 1.0
2
;
days
day
mg 1, days
2
750–1500
or
i.v.
2
;
2
dose
21
2
mg/m 150
increased mg/m
mg/kg
q4w q28d; for
mg/m
cycle
mg/m
mg/m
10 15, 1.25 q3w on starting dose 15, day
rate.
4 0.75 1.25 2.4–4.0
response
RR:
weeks;
bevacizumab erlotinib thalidomide lapatinib
4
therapies.
þ þ þ þ
Treatment
every
q4w:
targeted
Topotecan Topotecan Topotecan Topotecan
daily;
with
qd:
Phase II I II I
days;
28
combination
in
57
every
56
2008 q28d:
.,
58 59
topotecan
2008
.,
al
of al
et
2008 2007
days;
et
., .,
al
21
al
Trials et et
every
5.
Study McGonigle Schwartzberg Downs Molina q21d:
Table
!
2009 Informa UK Ltd www.cmrojournal.com Topotecan for relapsed ovarian cancer Sehouli & Oskay-O
¨
zcelik
9
Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34